Open an account

Marinus Pharmaceuticals

MRNS · NASDAQ

Price unavailable right now.

No price history for this range.

About MRNS

Marinus Pharmaceuticals focuses on creating therapies aimed at improving the lives of individuals affected by seizure disorders. The company is headquartered in Radnor, Pennsylvania and currently employs 165 full-time employees. The firm is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The firm is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). The company is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Employees
165
Headquarters
Radnor, Pennsylvania
Listed
Jul 31, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
marinuspharma.com

MRNS key statistics

This section is temporarily unavailable. Refresh to try again.

MRNS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 8.8% on average.

  1. Q4 FY22: reported -$0.76 per share against an estimate of -$0.7106
  2. Q1 FY23: reported -$0.67 per share against an estimate of -$0.7373
  3. Q2 FY23: reported -$0.61 per share against an estimate of -$0.7311
  4. Q3 FY23: reported -$0.61 per share against an estimate of -$0.6739
  5. Q4 FY23: reported -$0.74 per share against an estimate of -$0.6354
  6. Q1 FY24: reported -$0.68 per share against an estimate of -$0.6747
  7. Q2 FY24: reported -$0.60 per share against an estimate of -$0.6013
  8. Q3 FY24: reported -$0.42 per share against an estimate of -$0.4178

MRNS news

  • Press releaseGlobe Newswire

    MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  • Press releaseGlobe Newswire

    MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPY, HEES, MRNS on Behalf of Shareholders

  • Press releasePRNewswire

    $TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action

  • Press releasePRNewswire

    SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders

  • Press releaseBusiness Wire

    MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA, LBRDA on Behalf of Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders

Similar companies

Companies in the same industry as Marinus Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.